Eli Lilly and Company (LLY) Receives “Buy” Rating from Deutsche Bank AG
Deutsche Bank AG reissued their buy rating on shares of Eli Lilly and Company (NYSE:LLY) in a research note released on Monday morning. Deutsche Bank AG currently has a $91.00 price objective on the stock, up from their prior price objective of $90.00.
Several other brokerages have also issued reports on LLY. Zacks Investment Research raised Eli Lilly and from a hold rating to a buy rating and set a $94.00 price objective on the stock in a report on Monday. Jefferies Group LLC reaffirmed a buy rating and set a $96.00 price objective (up previously from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Citigroup Inc. reissued a buy rating and set a $100.00 price target on shares of Eli Lilly and in a report on Tuesday, July 4th. Barclays PLC raised their price target on Eli Lilly and from $85.00 to $90.00 and gave the stock an overweight rating in a report on Tuesday, July 4th. Finally, BidaskClub raised Eli Lilly and from a sell rating to a hold rating in a report on Wednesday, June 14th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the stock. Eli Lilly and currently has an average rating of Buy and a consensus price target of $87.75.
Shares of Eli Lilly and (LLY) traded down 0.35% on Monday, hitting $84.45. The stock had a trading volume of 396,283 shares. The firm has a market cap of $89.20 billion, a price-to-earnings ratio of 40.84 and a beta of 0.35. The stock has a 50 day moving average of $82.29 and a 200 day moving average of $81.07. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.22 billion. Eli Lilly and had a return on equity of 26.64% and a net margin of 10.13%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $0.83 earnings per share. Equities analysts predict that Eli Lilly and will post $4.12 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.45%. Eli Lilly and’s dividend payout ratio (DPR) is presently 100.48%.
In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the sale, the senior vice president now directly owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 474,733 shares of company stock worth $39,634,487. Company insiders own 0.20% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. First Command Financial Services Inc. increased its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co acquired a new stake in shares of Eli Lilly and during the first quarter worth $135,000. LeJeune Puetz Investment Counsel LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter worth $136,000. Point72 Asia Hong Kong Ltd increased its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares in the last quarter. Finally, Penserra Capital Management LLC increased its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares in the last quarter. 75.47% of the stock is owned by institutional investors and hedge funds.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.